AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT05398263
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 32
- Registration Number
- NCT05395117
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
PASS of Paediatric Patients Initiating Selumetinib
Recruiting
- Conditions
- Neurofibromatosis Type 1
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT05388370
- Locations
- 🇬🇧
Research Site, Newcastle, United Kingdom
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 183
- Registration Number
- NCT05384262
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
FAsenra Safety Trial in India
Phase 4
Completed
- Conditions
- In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 139
- Registration Number
- NCT05384938
- Locations
- 🇮🇳
Research Site, Vishakhapatnam, India
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
Phase 2
Terminated
- Conditions
- Coronavirus Disease 2019 (COVID-19)
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 251
- Registration Number
- NCT05375760
- Locations
- 🇺🇸
Research Site, Annandale, Virginia, United States
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
Phase 3
Active, not recruiting
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 644
- Registration Number
- NCT05374512
- Locations
- 🇬🇧
Research Site, Warwick, United Kingdom
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT05374603
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
Phase 1
Recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT05367440
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833
Phase 1
Completed
- Conditions
- ER-positive, HER2-negative Breast Cancer
- Interventions
- Drug: [14C]AZD9833 Oral Solution, 75 mg
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05364255
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath